Zobrazeno 1 - 10
of 207
pro vyhledávání: '"Angel Porgador"'
Autor:
Shosh Zismanov, Bar Shalem, Yulia Margolin-Miller, Dalia Rosin-Grunewald, Roy Adar, Ayelet Keren-Naus, Doron Amichay, Anat Ben-Dor, Yonat Shemer-Avni, Angel Porgador, Noam Shental, Tomer Hertz
Publikováno v:
Communications Medicine, Vol 4, Iss 1, Pp 1-9 (2024)
Abstract Background The SARS-CoV-2 pandemic led to unprecedented testing demands, causing major testing delays globally. One strategy used for increasing testing capacity was pooled-testing, using a two-stage technique first introduced during WWII. H
Externí odkaz:
https://doaj.org/article/a4b0f901b9b449d1b9d5ad13d523cac1
Autor:
Bar Kaufman, Tarek Taha, Orli Abramov, Yaniv Zohar, Kamel Mhameed, Ofir Cohen, Angel Porgador, Moshe Elkabets, Salem Billan
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-7 (2024)
Abstract Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional bind
Externí odkaz:
https://doaj.org/article/d5f6768c30924b929faf4d6be7a889a4
Publikováno v:
Journal of Extracellular Biology, Vol 3, Iss 9, Pp n/a-n/a (2024)
Abstract Cancer therapy is a dynamically evolving field, witnessing the emergence of innovative approaches that offer a promising outlook for patients grappling with persistent disease. Within the realm of therapeutic exploration, chimeric antigen re
Externí odkaz:
https://doaj.org/article/b718a740d64b4c4089483251985835d4
57 Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/061bee3b0a4e4081b0d8c5f5119b850d
Autor:
Omri Sharabi, Yariv Greenshpan, Noa Ofir, Aner Ottolenghi, Tamar Levi, Leonid Olender, Zachor Adler-Agmon, Angel Porgador, Roi Gazit
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Cancer immunotherapies are highly potent and are gaining wide clinical usage. However, severe side effects require focusing effector immune cell activities on the tumor microenvironment (TME). We recently developed a chimeric antigen recepto
Externí odkaz:
https://doaj.org/article/a8c3491aaadb47f198961624d9339fd6
Autor:
Vladimir Lazar, Jacques Raynaud, Shai Magidi, Catherine Bresson, Jean-François Martini, Susan Galbraith, Fanny Wunder, Amir Onn, Gerald Batist, Nicolas Girard, Ulrik Lassen, C. S. Pramesh, Amal Al-Omari, Sadakatsu Ikeda, Guy Berchem, Jean-Yves Blay, Benjamin Solomon, Enriqueta Felip, Josep Tabernero, Eitan Rubin, Thierry Philip, Angel Porgador, Ioana Berindan-Neagoe, Richard L. Schilsky, Razelle Kurzrock
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: SARS-CoV-2 (COVID-19) elicits a T-cell antigen-mediated immune response of variable efficacy. To understand this variability, we explored transcriptomic expression of angiotensin-converting enzyme 2 ( ACE2 , the SARS-CoV-2 receptor) and o
Externí odkaz:
https://doaj.org/article/cacbf20affbf406896e87fc22d539ae7
Autor:
Aner Ottolenghi, Priyanka Bolel, Rhitajit Sarkar, Yariv Greenshpan, Muhammed Iraqi, Susmita Ghosh, Baisali Bhattacharya, Zoe V. Taylor, Kiran Kundu, Olga Radinsky, Roi Gazit, David Stepensky, Ron N. Apte, Elena Voronov, Angel Porgador
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract IL-2 is the master-regulator cytokine for T cell dependent responses and is crucial for proliferation and survival of T cells. However, IL-2-based treatments remained marginal, in part due to short half-life. Thus, we aimed to extend IL-2 ha
Externí odkaz:
https://doaj.org/article/ad6cc7eb08a2453fb99bf074bf0f2812
Autor:
Vladimir Lazar, Shai Magidi, Nicolas Girard, Alexia Savignoni, Jean-François Martini, Giorgio Massimini, Catherine Bresson, Raanan Berger, Amir Onn, Jacques Raynaud, Fanny Wunder, Ioana Berindan-Neagoe, Marina Sekacheva, Irene Braña, Josep Tabernero, Enriqueta Felip, Angel Porgador, Claudia Kleinman, Gerald Batist, Benjamin Solomon, Apostolia Maria Tsimberidou, Jean-Charles Soria, Eitan Rubin, Razelle Kurzrock, Richard L. Schilsky
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
Abstract The expanding targeted therapy landscape requires combinatorial biomarkers for patient stratification and treatment selection. This requires simultaneous exploration of multiple genes of relevant networks to account for the complexity of mec
Externí odkaz:
https://doaj.org/article/03d1a19c53bf406b8f14275e04c89c95
Autor:
Yariv Greenshpan, Omri Sharabi, Aner Ottolenghi, Avishag Cahana, Kiran Kundu, Ksenia M. Yegodayev, Moshe Elkabets, Roi Gazit, Angel Porgador
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-11 (2021)
Greenshpan et al. explore the use of synthetic promoters based on IFNgamma, TNF alpha and hypoxia responsive elements to control gene expression. The authors describe this technology in the context of chimeric antigen expression (CAR) and propose tha
Externí odkaz:
https://doaj.org/article/e0c47efecb0d4ae69091de751e705b6f
Autor:
Esti Toledo, Sharon Dim, Avishay Edri, Yariv Greenshpan, Aner Ottolenghi, Nadav Eisner, Sivan Tzadka, Ashish Pandey, Haggai Ben Nun, Guillaume Le Saux, Angel Porgador, Mark Schvartzman
Publikováno v:
PLoS ONE, Vol 17, Iss 8, p e0272307 (2022)
The current Covid-19 pandemic has a profound impact on all aspects of our lives. Aside from contagion by aerosols, the presence of the SARS-CoV-2 is ubiquitous on surfaces that millions of people handle daily. Therefore, controlling this pandemic inv
Externí odkaz:
https://doaj.org/article/2d7bf685d13f4dd690a5d1c0b2cc98ce